Versor Investments LP Buys New Shares in Agilent Technologies, Inc. (NYSE:A)

Versor Investments LP bought a new stake in Agilent Technologies, Inc. (NYSE:A) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 8,546 shares of the medical research company’s stock, valued at approximately $1,269,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Crewe Advisors LLC increased its position in Agilent Technologies by 114.8% during the second quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock worth $25,000 after buying an additional 101 shares during the last quarter. Livelsberger Financial Advisory acquired a new position in Agilent Technologies during the third quarter worth approximately $28,000. Ridgewood Investments LLC acquired a new position in Agilent Technologies during the second quarter worth approximately $29,000. Ashton Thomas Securities LLC acquired a new position in Agilent Technologies during the third quarter worth approximately $31,000. Finally, Fortitude Family Office LLC increased its position in Agilent Technologies by 68.3% during the third quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company’s stock worth $35,000 after buying an additional 95 shares during the last quarter.

Insiders Place Their Bets

In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the completion of the sale, the senior vice president now directly owns 40,011 shares in the company, valued at approximately $5,801,595. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, SVP Dominique Grau sold 9,990 shares of the firm’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $145.00, for a total value of $1,448,550.00. Following the completion of the sale, the senior vice president now directly owns 40,011 shares in the company, valued at $5,801,595. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total value of $283,910.00. Following the completion of the sale, the chief executive officer now owns 24,118 shares of the company’s stock, valued at approximately $3,497,110. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,995 shares of company stock worth $1,739,510.

Analysts Set New Price Targets

A has been the topic of a number of research reports. Wells Fargo & Company began coverage on Agilent Technologies in a report on Tuesday, August 27th. They issued an “overweight” rating and a $157.00 price objective on the stock. Citigroup raised their price target on shares of Agilent Technologies from $150.00 to $165.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Stifel Nicolaus reissued a “buy” rating and issued a $151.00 price objective on shares of Agilent Technologies in a report on Monday, August 26th. Evercore ISI boosted their price objective on shares of Agilent Technologies from $135.00 to $145.00 and gave the company an “in-line” rating in a report on Tuesday, October 1st. Finally, UBS Group increased their price target on Agilent Technologies from $141.00 to $150.00 and gave the stock a “neutral” rating in a research report on Thursday, August 22nd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $144.36.

Agilent Technologies Stock Performance

NYSE A opened at $133.86 on Tuesday. The company has a market capitalization of $38.46 billion, a price-to-earnings ratio of 27.77, a PEG ratio of 6.01 and a beta of 1.07. Agilent Technologies, Inc. has a twelve month low of $106.96 and a twelve month high of $155.35. The stock has a fifty day simple moving average of $139.46 and a 200 day simple moving average of $138.21. The company has a quick ratio of 1.37, a current ratio of 1.78 and a debt-to-equity ratio of 0.36.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Wednesday, August 21st. The medical research company reported $1.32 earnings per share for the quarter, beating analysts’ consensus estimates of $1.26 by $0.06. The business had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.56 billion. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. Agilent Technologies’s quarterly revenue was down 5.6% on a year-over-year basis. During the same period in the prior year, the business posted $1.43 earnings per share. Sell-side analysts expect that Agilent Technologies, Inc. will post 5.24 EPS for the current year.

Agilent Technologies Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, October 23rd. Shareholders of record on Tuesday, October 1st were issued a dividend of $0.236 per share. The ex-dividend date was Tuesday, October 1st. This represents a $0.94 dividend on an annualized basis and a yield of 0.71%. Agilent Technologies’s payout ratio is currently 19.50%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.